Alector stock hits 52-week low at $1.59 amid market challenges
In a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a new 52-week low, with shares plummeting to $1.59. This significant downturn reflects a broader trend for the ...
Pharm Exec2h
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...
PMLiVE8h
AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
cidrap.umn23h
WHO identifies research priorities for boosting fight against antimicrobial resistance
The global research agenda includes 33 research priorities for bacterial and fungal infections and 7 for drug-resistant ...
Elon Musk's OpenAI Bid A 'Distraction' From Tesla's Challenges
Tesla stock continued its recent slide Tuesday following news late Monday that Elon Musk has led a takeover bid for OpenAI.
Healio23h
Upadacitinib, deucravacitinib ‘the top two’ small molecules for psoriatic arthritis
Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal ...